Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00037011 · ClinicalTrials.gov registry record · Phase 1
Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00037011: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00037011 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00037011, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Biological therapies such as beta-glucan use different ways to stimulate the immune system and stop cancer cells from growing. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining beta-glucan and monoclonal antibody may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining beta-glucan and monoclonal antibody in treating patients who have metastatic neuroblastoma.
Interventions
- BIOLOGICAL monoclonal antibody 3F8
- BIOLOGICAL beta-glucan
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00037011
The ClinicalTrials.gov registry entry for NCT00037011 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which monoclonal antibody 3F8 is the first listed.
NCT00037011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00037011 about?
NCT00037011 is a clinical study titled "Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma". RATIONALE: Biological therapies such as beta-glucan use different ways to stimulate the immune system and stop cancer cells from growing. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining beta-glucan ...
What is the current status of trial NCT00037011?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-11.
What interventions are being tested in trial NCT00037011?
The interventions under investigation include: monoclonal antibody 3F8 (BIOLOGICAL), beta-glucan (BIOLOGICAL).
Who is sponsoring clinical trial NCT00037011?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.